Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile an
about
HIV-1 RT Inhibitors with a Novel Mechanism of Action: NNRTIs that Compete with the Nucleotide SubstrateAmino acid deletion at codon 67 and Thr-to-Gly change at codon 69 of human immunodeficiency virus type 1 reverse transcriptase confer novel drug resistance profilesStructure-based design of novel dihydroalkoxybenzyloxopyrimidine derivatives as potent nonnucleoside inhibitors of the human immunodeficiency virus reverse transcriptaseCharacteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1Identification of drug resistant mutations in HIV-1 CRF07_BC variants selected by nevirapine in vitroRT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy.Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primerHigh-level resistance to 3'-azido-3'-deoxythimidine due to a deletion in the reverse transcriptase gene of human immunodeficiency virus type 1Relative replication fitness of a high-level 3'-azido-3'-deoxythymidine-resistant variant of human immunodeficiency virus type 1 possessing an amino acid deletion at codon 67 and a novel substitution (Thr-->Gly) at codon 69.The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Genotypic testing for human immunodeficiency virus type 1 drug resistance.A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V.Characterization and structural analysis of novel mutations in human immunodeficiency virus type 1 reverse transcriptase involved in the regulation of resistance to nonnucleoside inhibitors.Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTClinical significance of human immunodeficiency virus type 1 replication fitness.HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillanceThe Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors.Nonpolymorphic human immunodeficiency virus type 1 protease and reverse transcriptase treatment-selected mutations.Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity.Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication.The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development.Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors.Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.Characterization of amino acids Arg, Ser and Thr at position 70 within HIV-1 reverse transcriptase.Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility.
P2860
Q28250395-9C02EA09-D038-4163-88C9-B7380481DE8EQ28361269-A394858E-6CBB-4B60-9CAE-54B83E2FF612Q28369309-76FB523E-A58B-470E-9310-12838DF2BACFQ28379192-4C83B1F4-30FB-4C5C-B506-39BE8CEB4AF4Q28483726-7248FF04-59F5-4DC1-9BBE-5AF16E14AC2EQ33514943-1CF40060-4F5C-4F6B-90DD-2B89FAFE1511Q33649563-433B09CE-A664-4547-A664-049A5DC799F5Q33690164-044FAD36-AAAB-48E7-BA36-34B4F59F6D4FQ33796791-81C7F163-F3BA-4E15-B594-AF2BF5D64758Q33826453-2639EDFD-5123-46F0-8E93-1A91654B2B31Q33872810-604D31D4-B952-4DA7-816E-9574F82552CEQ33906239-D37B1D6D-A3DE-4F92-B80A-9B3089D6167CQ35742512-3A772A7C-B531-4CD7-9E58-31CCAAA07D74Q35794287-E2BAB06A-3DDF-4815-B57E-244B93082DDDQ36099251-BCEAB3C6-6FF6-439C-A66A-79448B5EBFD3Q36250342-739406C8-E006-4628-8DD4-422818C29811Q36900010-9323F8CC-1310-4F9D-A1FA-B85F06EA6680Q36969857-BB4FB620-B10E-41D7-B5B7-E3F91E6CB61FQ37003252-CE5C43D7-5FBE-4BC9-87EB-054FE3763051Q37018369-07E01D53-4016-4E5F-B117-760FA5B71097Q37409842-6EB390FC-76A4-4019-B4CC-F1AA84C92519Q39142877-A582C2FF-87D4-454F-8F52-CFCBBDD1A1A5Q39595110-BAB59CC2-6EB7-48C1-9DF1-C494B135ED0FQ39699409-364EAC7C-A466-4A0A-A6F6-0F998A21CB6DQ40012022-E47D2C13-3909-479C-91B1-DCD2DF64BA21Q40013658-98D8274E-A578-48FA-9AD1-2CA4EC536EAFQ41474077-E51836E2-290B-4989-81F7-956C6CC757ACQ41720036-F038A9BF-4098-4F3D-940B-FE930296FD68Q41892773-E0EE20F1-AE85-4200-903B-17DFC7B06BD9Q42062012-112A36F1-B814-4273-9CB5-7A4CDF2B5C71Q42101552-2F45BFEA-C77F-4590-AECD-611DC16614DEQ42201246-6C11A653-688A-4DCE-86B4-E96C7F755C37Q43077557-D459C18C-2655-4C0D-B94B-C6E71DCE6250
P2860
Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile an
description
1996 nî lūn-bûn
@nan
1996 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Selective pressure of a quinox ...... fic (RT Leu-74-->Val or Ile an
@nl
type
label
Selective pressure of a quinox ...... fic (RT Leu-74-->Val or Ile an
@nl
prefLabel
Selective pressure of a quinox ...... fic (RT Leu-74-->Val or Ile an
@nl
P2093
P2860
P356
P1476
Selective pressure of a quinox ...... 75-->Leu or Ile) HIV-1 mutants
@en
P2093
A Paessens
P2860
P356
10.1073/PNAS.93.1.34
P407
P577
1996-01-09T00:00:00Z